Idorsia News Today

**Viatris and Idorsia Forge Major Global R&D Alliance** **Allschwil, Switzerland - September 6, 2023** - WEB Viatris and Idorsia announced today a significant global research and development collaboration. The partnership will focus on developing and commercializing novel therapies in areas of unmet medical need. Financial news from Idorsia also emerged, with the company releasing its financial results for the first nine months of 2023. Additionally, the U.S. Food and Drug Administration (FDA) has granted approval to one of Idorsia's products. In other developments, Idorsia announced the successful completion of PRECISION, its Phase 3 study of a new treatment. The company also announced the start of a cost reduction initiative to streamline its operations. **Collaboration Details** The Viatris-Idorsia collaboration will leverage the expertise and resources of both companies. Viatris's global reach and commercialization capabilities will complement Idorsia's innovative pipeline and research capabilities. The partnership aims to bring new therapies to patients faster and more effectively. **Key Highlights** * IDIA's financial results for the first nine months of 2023 were positive. * FDA approval of IDIA's product is a significant milestone. * Positive results from the PRECISION Phase 3 study indicate potential for a new treatment. * IDIA's cost reduction initiative is expected to improve efficiency and reduce expenses. * The Viatris-Idorsia collaboration combines the strengths of two industry leaders. This collaboration is expected to accelerate the development and delivery of innovative therapies that address critical unmet medical needs.